WO2021006599A1 - Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물 - Google Patents
Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물 Download PDFInfo
- Publication number
- WO2021006599A1 WO2021006599A1 PCT/KR2020/008855 KR2020008855W WO2021006599A1 WO 2021006599 A1 WO2021006599 A1 WO 2021006599A1 KR 2020008855 W KR2020008855 W KR 2020008855W WO 2021006599 A1 WO2021006599 A1 WO 2021006599A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sialic acid
- polypeptide dimer
- acid content
- ige
- glu
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 186
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 186
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 186
- 239000000539 dimer Substances 0.000 title claims abstract description 164
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 title claims abstract description 135
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 title claims abstract description 130
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 26
- 102000009109 Fc receptors Human genes 0.000 title claims abstract description 17
- 108010087819 Fc receptors Proteins 0.000 title claims abstract description 17
- 208000026935 allergic disease Diseases 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims description 30
- 150000001413 amino acids Chemical group 0.000 claims description 21
- 108060003951 Immunoglobulin Proteins 0.000 claims description 19
- 102000018358 immunoglobulin Human genes 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 17
- 206010016946 Food allergy Diseases 0.000 claims description 17
- 235000020932 food allergy Nutrition 0.000 claims description 17
- 239000000178 monomer Substances 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 15
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims description 14
- 208000010668 atopic eczema Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 7
- 230000000172 allergic effect Effects 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims description 5
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- IMAKMJCBYCSMHM-AVGNSLFASA-N Lys-Glu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN IMAKMJCBYCSMHM-AVGNSLFASA-N 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 208000030949 chronic idiopathic urticaria Diseases 0.000 claims description 4
- 206010072757 chronic spontaneous urticaria Diseases 0.000 claims description 4
- 208000024376 chronic urticaria Diseases 0.000 claims description 4
- 108010009298 lysylglutamic acid Proteins 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- NXDXECQFKHXHAM-HJGDQZAQSA-N Arg-Glu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NXDXECQFKHXHAM-HJGDQZAQSA-N 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 3
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 claims description 3
- OWVURWCRZZMAOZ-XHNCKOQMSA-N Glu-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)N)C(=O)O OWVURWCRZZMAOZ-XHNCKOQMSA-N 0.000 claims description 3
- BUZMZDDKFCSKOT-CIUDSAMLSA-N Glu-Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O BUZMZDDKFCSKOT-CIUDSAMLSA-N 0.000 claims description 3
- BDFHWFUAQLIMJO-KXNHARMFSA-N Lys-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N)O BDFHWFUAQLIMJO-KXNHARMFSA-N 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 108010070643 prolylglutamic acid Proteins 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- CZPAHAKGPDUIPJ-CIUDSAMLSA-N Ala-Gln-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(O)=O CZPAHAKGPDUIPJ-CIUDSAMLSA-N 0.000 claims description 2
- QUIGLPSHIFPEOV-CIUDSAMLSA-N Ala-Lys-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O QUIGLPSHIFPEOV-CIUDSAMLSA-N 0.000 claims description 2
- ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 claims description 2
- RZSLYUUFFVHFRQ-FXQIFTODSA-N Gln-Ala-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O RZSLYUUFFVHFRQ-FXQIFTODSA-N 0.000 claims description 2
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 claims description 2
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 claims description 2
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 claims description 2
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 claims description 2
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 claims description 2
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 claims description 2
- JMZKMSTYXHFYAK-VEVYYDQMSA-N Thr-Arg-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O JMZKMSTYXHFYAK-VEVYYDQMSA-N 0.000 claims description 2
- KCRQEJSKXAIULJ-FJXKBIBVSA-N Thr-Gly-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O KCRQEJSKXAIULJ-FJXKBIBVSA-N 0.000 claims description 2
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 claims description 2
- 108010087924 alanylproline Proteins 0.000 claims description 2
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 claims description 2
- 108010054155 lysyllysine Proteins 0.000 claims description 2
- 108010061238 threonyl-glycine Proteins 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000005629 sialic acid group Chemical group 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- 108010073807 IgG Receptors Proteins 0.000 abstract description 16
- 102000009490 IgG Receptors Human genes 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract description 10
- 208000003455 anaphylaxis Diseases 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 7
- 230000036783 anaphylactic response Effects 0.000 abstract description 6
- 230000002688 persistence Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 229960000470 omalizumab Drugs 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 38
- 239000000523 sample Substances 0.000 description 37
- 241000699670 Mus sp. Species 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 108010058846 Ovalbumin Proteins 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 230000003266 anti-allergic effect Effects 0.000 description 18
- 229940092253 ovalbumin Drugs 0.000 description 18
- 108010073816 IgE Receptors Proteins 0.000 description 16
- 102000009438 IgE Receptors Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 206010012735 Diarrhoea Diseases 0.000 description 13
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 238000010586 diagram Methods 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 101710169891 Mast cell protease 1 Proteins 0.000 description 11
- FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-beta-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 description 11
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 11
- 238000012790 confirmation Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000011534 wash buffer Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 description 8
- 101710128966 High affinity immunoglobulin epsilon receptor subunit alpha Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 6
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 229940099073 xolair Drugs 0.000 description 6
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 108090000992 Transferases Proteins 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010021472 Fc gamma receptor IIB Proteins 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 210000003651 basophil Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010021468 Fc gamma receptor IIA Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 239000010421 standard material Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- XTRHYDMWPCTCKN-UHFFFAOYSA-N 2-phosphonooxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(CC(O)=O)(OP(O)(O)=O)C(O)=O XTRHYDMWPCTCKN-UHFFFAOYSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 2
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- OMRLTNCLYHKQCK-DHGKCCLASA-N 4-nitrophenyl N-acetyl-beta-D-glucosaminide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([N+]([O-])=O)C=C1 OMRLTNCLYHKQCK-DHGKCCLASA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ILGFBUGLBSAQQB-GUBZILKMSA-N Glu-Glu-Arg Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ILGFBUGLBSAQQB-GUBZILKMSA-N 0.000 description 1
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 1
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000013077 target material Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003588 threonines Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 230000002568 urticarial effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to a polypeptide dimer comprising the IgE Fc receptor and a high sialic acid content, and a pharmaceutical composition comprising the same.
- IgE immunoglobulin E
- IgE immunoglobulin E
- Fc ⁇ RI high-affinity IgE receptor
- mast cells or basophilic granulocytes release chemical mediators such as histamine, leukotriene, prostaglandin, bradykinin, and platelet-activating factors.
- Allergic symptoms are caused by the released chemical mediators.
- allergic diseases may worsen symptoms due to the combination of IgE and Fc ⁇ RI.
- Fc ⁇ RI high-affinity IgE receptor
- Omalizumab (trade name: Xolair), which targets the Fc portion of IgE, has been developed and is used as a treatment for refractory severe asthma and refractory urticaria.
- omalizumab must be administered at a high dose to maintain the effect, so the cost is high, and side effects such as angioedema and anaphylaxis reactions are reported (The Journal of Clinical Investigation Volume 99, Number 5, March 1997, 915. -925).
- serious adverse reactions such as allergic granulomatous vasculitis and idiopathic severe thrombocytopenia have been reported after the marketing.
- the present inventors studied to develop a safe and effective treatment for allergic diseases.
- the sialic acid content of the polypeptide dimer containing two monomers (Fc ⁇ RI ⁇ -ECD) containing the extracellular domain of the alpha subunit of the IgE Fc receptor is high, the polypeptide dimer has only excellent binding ability with IgE. Rather, it was found that the blood concentration was maintained high.
- the present invention was completed by confirming that effective delivery into the body is possible even when the polypeptide dimer having a high sialic acid content is administered subcutaneously.
- One aspect of the present invention provides a polypeptide dimer comprising two monomers comprising the extracellular domain (Fc ⁇ RI ⁇ -ECD) of the alpha subunit of the IgE Fc receptor, wherein the molar ratio of the sialic acid/polypeptide dimer is at least 8 to provide.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating allergic diseases comprising a polypeptide dimer having a high sialic acid content.
- Another aspect of the present invention provides a transdermal patch comprising the pharmaceutical composition.
- Another aspect of the present invention provides a topical patch comprising the pharmaceutical composition.
- Another aspect of the present invention provides a food composition for improving or alleviating allergic symptoms comprising a polypeptide dimer having a high sialic acid content.
- Another aspect of the present invention provides the use of the polypeptide dimer having a high sialic acid content for the prevention or treatment of allergic diseases.
- the polypeptide dimer having a high sialic acid content according to the present invention not only has superior persistence and safety in the body compared to the conventional anti-IgE antibody, but also strongly binds to IgE, so it has the advantage of extending the administration cycle.
- the polypeptide dimer having a high sialic acid content according to the present invention is an IgE single target material, and does not bind to the Fc gamma receptor, unlike the conventional anti-IgE antibody to which Fc of IgG1 is applied.
- a polypeptide dimer having a high sialic acid content can maintain a high blood concentration even when administered subcutaneously. Therefore, the polypeptide dimer having a high sialic acid content according to the present invention can be usefully used in the prevention or treatment of allergic diseases.
- 1 is a diagram showing the results of confirming the polypeptide dimers produced in each cell line by SDS-PAGE.
- FIG. 2 is a diagram showing the results of SDS-PAGE of the non-reduced and reduced forms of a polypeptide dimer according to an embodiment.
- Figure 3 is a diagram showing the binding ability of omalizumab to IgE.
- FIG. 4 is a diagram showing the binding ability of a polypeptide dimer (IgE TRAP ) to IgE according to an embodiment.
- Figure 5a is a diagram showing the binding ability of a specific example of a polypeptide dimer (IgE TRAP ) or omalizumab and IgG Fc gamma receptor I (Fc ⁇ RI).
- IgE TRAP polypeptide dimer
- Fc ⁇ RI IgG Fc gamma receptor I
- Figure 5b is a diagram showing the binding ability of a specific example of the polypeptide dimer (IgE TRAP ) or omalizumab and IgG Fc gamma receptor IIA (Fc ⁇ RIIA).
- IgE TRAP polypeptide dimer
- Fc ⁇ RIIA IgG Fc gamma receptor IIA
- Figure 5c is a diagram showing the binding ability of a specific example of the polypeptide dimer (IgE TRAP ) or omalizumab and IgG Fc gamma receptor IIB (Fc ⁇ RIIB).
- IgE TRAP polypeptide dimer
- Fc ⁇ RIIB IgG Fc gamma receptor IIB
- Figure 5d is a diagram showing the binding ability of a specific example of the polypeptide dimer (IgE TRAP ) or omalizumab and IgG Fc gamma receptor IIIA (Fc ⁇ RIIIA).
- IgE TRAP polypeptide dimer
- Fc ⁇ RIIIA IgG Fc gamma receptor IIIA
- Figure 5e is a diagram showing the binding ability of the Fc gamma receptor IIIB (Fc ⁇ RIIIB) of a specific example polypeptide dimer (IgE TRAP ) or omalizumab and IgG.
- FIG. 6 is a graph showing the quantification of the binding power of an exemplary polypeptide dimer (IgE TRAP ) or omalizumab to the Fc gamma receptors of IgG.
- FIG. 7 is a diagram showing the degree of binding to IgE according to the concentration of the polypeptide dimer according to an embodiment.
- FIG. 8 is a view comparing the activity inhibitory ability of mast cells derived from human Fc ⁇ RI-expressing mice according to the concentration of the polypeptide dimer protein (IgE TRAP ) and Xolere (omalizumab) according to an embodiment.
- IgE TRAP polypeptide dimer protein
- Xolere omalizumab
- 9 is a view confirming the anti-allergic effect of the polypeptide dimer according to an embodiment through the measurement of the incidence of diarrhea in a food allergy model.
- FIG. 10 is a view showing the results of SDS-PAGE of the non-reduced and reduced forms of the polypeptide dimers (SA low , SA medi and SA high ) according to an embodiment.
- FIG. 11 is a diagram illustrating the isoelectric point of a polypeptide dimer (SA low , SA medi and SA high ) according to an embodiment.
- FIG. 12 is a view confirming the anti-allergic effect according to subcutaneous injection of the polypeptide dimer (SA low and SA high ) of one embodiment through the measurement of the incidence of diarrhea in a food allergy model.
- FIG. 13 is a view confirming the anti-allergic effect of the polypeptide dimers (SA low and SA high ) according to an embodiment through the measurement of blood IgE concentration in a food allergy model.
- FIG. 14 is a view confirming the anti-allergic effect of the polypeptide dimers (SA low and SA high ) according to an embodiment through the measurement of blood MCPT-1 concentration in a food allergy model.
- 15 is a diagram showing the pharmacokinetic profile analysis result of a specific example polypeptide dimer according to the sialic acid content in a mouse model.
- 16 is a view confirming the anti-allergic effect according to the sialic acid content of an exemplary polypeptide dimer through body temperature measurement in a passive systemic anaphylaxis mouse model.
- One aspect of the present invention is a polypeptide dimer comprising two monomers containing the extracellular domain (Fc ⁇ RIa-ECD) of the alpha subunit of the IgE Fc receptor, the monomer comprising an Fc region, the Fc region and Fc ⁇ RIa-ECD is bound through a hinge, and the polypeptide dimer provides a polypeptide dimer having a high sialic acid content, characterized in that the molar ratio of sialic acid/polypeptide dimer is at least 8.
- IgE used in the present invention refers to an antibody known as immunoglobulin E. IgE has affinity for mast cells and basophils. In addition, when IgE and its corresponding antigen (allergen) react, it causes an inflammatory reaction. In addition, IgE is known to be the main cause of anaphylaxis.
- IgE Fc receptor used in the present invention is also called an Fc ⁇ receptor, and refers to a receptor that binds to the Fc portion of IgE.
- Fc ⁇ RI Fc ⁇ receptor I
- Fc ⁇ RII Fc ⁇ receptor II
- Fc ⁇ RI Fc ⁇ receptor I
- Fc ⁇ RII Fc ⁇ receptor II
- the Fc ⁇ RI is a membrane protein composed of one ⁇ -chain, one ⁇ -chain, and two ⁇ -chains bonded by disulfide bonds.
- the part to which IgE binds is an ⁇ chain (Fc ⁇ RI ⁇ )
- Fc ⁇ RI ⁇ has a size of about 60 kDa, and is composed of a hydrophobic domain present in the cell membrane and a hydrophilic domain present outside the cell membrane.
- IgE binds to the extracellular domain of the ⁇ chain.
- the Fc ⁇ RI ⁇ may be used interchangeably as an alpha subunit of the IgE Fc receptor.
- the alpha subunit of the IgE Fc receptor may consist of the amino acid sequence described in NP_001992.1.
- the extracellular domain (Fc ⁇ RIa-ECD) of the alpha subunit of the IgE Fc receptor may be composed of the amino acid sequence of SEQ ID NO: 1.
- the Fc ⁇ RIa-ECD may be a fragment of Fc ⁇ RIa-ECD or a variant thereof, as long as it can bind to IgE.
- Fc ⁇ RIa-ECD of SEQ ID NO: 1 may be encoded by a polynucleotide represented by SEQ ID NO: 5.
- the variant may be performed through a method of substituting, deleting or adding one or more amino acids in wild-type Fc ⁇ RIa-ECD, as long as the function of Fc ⁇ RIa-ECD is not modified.
- the variant may have 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more homology with the amino acid sequence of SEQ ID NO: 1.
- the Fc region may be a wild-type Fc region or a modified Fc region.
- the term "modified Fc region" used in the present invention refers to a region in which part of the Fc portion of an antibody has been modified.
- the Fc region includes a heavy chain constant region 2 (CH2) and a heavy chain constant region 3 (CH3) of an immunoglobulin, and does not include the variable regions of the heavy and light chain and the light chain constant region 1 (CH1) of the immunoglobulin.
- the modified Fc region may be prepared by substituting some amino acids in the Fc region or combining different types of Fc regions.
- the modified Fc region may be composed of the amino acid sequence of SEQ ID NO: 2.
- the modified Fc region of SEQ ID NO: 2 may be encoded by a polynucleotide represented by SEQ ID NO: 6.
- the modified Fc region may be a natural sugar chain or an increased sugar chain compared to the natural type.
- the immunoglobulin Fc sugar chain can be modified by conventional methods such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms.
- the modified Fc region does not have a binding site for the Fc gamma receptor (Fc ⁇ R) or C1q (complement component 1q), and thus may be lacking the functions of ADCC (antibody dependent cellular cytotoxicity) and CDC (Complement dependent Cytotoxicity). .
- the modified Fc region may be coupled through the hinge of Fc ⁇ RI ⁇ -ECD and IgD.
- the hinge may be a hinge region derived from immunoglobulin IgD or a variant thereof.
- the hinge region of native IgD consists of 64 amino acids.
- the hinge region derived from the immunoglobulin IgD or a variant thereof may be composed of 20 to 60 consecutive amino acids, 25 to 50 consecutive amino acids, or 30 to 40 amino acids.
- the hinge variant may be a partial modification of the amino acid sequence of the hinge region of IgD in order to minimize the occurrence of a truncated form during protein production.
- the hinge region derived from the immunoglobulin IgD or a variant thereof may be composed of 30 or 49 amino acids.
- the hinge region derived from the immunoglobulin IgD or a variant thereof may include at least one cysteine.
- the hinge region or a variant thereof derived from the immunoglobulin IgD may include the following sequence:
- Xaa1 may be Lys or Gly
- Xaa2 is Glu , Gly or Ser.
- the hinge region derived from the immunoglobulin IgD or a variant thereof may have an amino acid sequence of SEQ ID NO: 3 and SEQ ID NO: 19, thereby minimizing the occurrence of a truncated form during protein production.
- the hinge region or a variant thereof derived from the immunoglobulin IgD may include the following sequence:
- Xaa3 is Lys or Gly
- Xaa4 may be Glu, Gly or Ser.
- the hinge region derived from the immunoglobulin IgD or a variant thereof may have the amino acid sequence of SEQ ID NO: 4, thereby minimizing the occurrence of a truncated form during protein production.
- threonine in the hinge region derived from the immunoglobulin IgD consisting of the amino acid represented by SEQ ID NO: 4 or a variant thereof, at least one of threonine (Thr) may be glycosylation.
- threonine of the 13th, 14th, 18th and 19th amino acid sequence represented by SEQ ID NO: 18 may be glycosylated.
- all four threonines can be glycosylated.
- the saccharification may be O-glycosylation.
- sugar chain attached to glycoprotein drugs is one of the main factors that determine quality as it plays an important role in therapeutic efficacy, persistence in the body, targeting and immune response. It was confirmed that the polypeptide dimer whose end of the sugar chain did not end with sialic acid was rapidly removed from the body.
- sialic acid used in the present invention may include N-acetylneuraminic acid (Neu5Ac) of Formula 1 and N-glycorylneuraminic acid (Neu5Gc) of Formula 2:
- the polypeptide dimer having a high sialic acid content may have a high content of N-acetylneuraminic acid.
- the sialic acid content of the polypeptide dimer can be increased through a purification method.
- the sialic acid content of the polypeptide dimer can be increased.
- the polypeptide dimer having a high sialic acid content may be characterized in that the molar ratio of sialic acid/polypeptide dimer is 8 or more.
- the sialic acid-rich polypeptide dimer has a sialic acid/polypeptide dimer molar ratio (mol/mol) of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 , 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30.
- the polypeptide dimer having a high sialic acid content has a molar ratio of sialic acid/polypeptide dimer of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, It may be 23, 24 or 25.
- the polypeptide dimer having a high sialic acid content has a molar ratio of sialic acid/polypeptide dimer of at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21.
- the molar ratio of the sialic acid/polypeptide dimer of the polypeptide dimer having a high sialic acid content may be 8 to 30, or 12 to 25.
- the sialic acid/polypeptide dimer molar ratio of the polypeptide dimer having a high sialic acid content may be 10 to 25, 11 to 24, 12 to 23.
- the molar ratio of the sialic acid/polypeptide dimer of the polypeptide dimer having a high sialic acid content is 13 to 22, 14 to 22, 15 to 22, 16 to 22, 17 to 22, 18 to 22 or 19 to 22 days.
- the sialic acid may be N-acetylneuraminic acid.
- the sialic acid may bind to 8 positions in the monomer including the extracellular domain (Fc ⁇ RIa-ECD) and the Fc region of the alpha subunit of the IgE Fc receptor. At this time, sialic acid may be bonded to at least four or more of the positions. Specifically, the sialic acid may be bonded to the monomer at 4, 5, 6, 7 or 8 positions.
- the polypeptide dimer having a high sialic acid content provided by the present invention may be in a form in which two monomers to which an extracellular domain of the alpha subunit of the IgE Fc receptor and a modified Fc region are bound are combined.
- the polypeptide dimer having a high sialic acid content may be a form in which two identical monomers are bonded by a cysteine located at a hinge site.
- the polypeptide dimer having a high sialic acid content may be in a form in which two different monomers are combined.
- each of the polypeptide monomers may include sialic acid at the same position, but may include sialic acid at different positions.
- the molar ratio of the sialic acid/polypeptide dimer is 8 or more, each of the monomers constituting the dimer may have a different molar ratio of sialic acid/polypeptide.
- the polypeptide dimer may contain two different monomers.
- one monomer may include the extracellular domain of the alpha subunit of the IgE Fc receptor, and the other monomer may be a form including a fragment of the extracellular domain of the alpha subunit of the IgE Fc receptor.
- one specific example of the monomer may be composed of an amino acid sequence represented by SEQ ID NO: 20, SEQ ID NO: 21, or SEQ ID NO: 22.
- polypeptide dimer having a high sialic acid content provided by the present invention is 10 to 100 times, 20 to 90 times, 20 to 70 times, 30 to 70 times or 40 to 70 times higher IgE than omalizumab, an anti-IgE antibody.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating allergic diseases comprising a polypeptide dimer having a high sialic acid content.
- the polypeptide dimer is the same as described above.
- the pharmaceutical composition may be characterized in that it is for subcutaneous injection.
- a polypeptide dimer having a high sialic acid content it was confirmed that it is effective in the treatment and/or prevention of allergic diseases compared to a polypeptide dimer having a low sialic acid content upon subcutaneous injection.
- allergic disease used in the present invention refers to a pathological condition caused by an allergic reaction mediated by the activation of mast cells, such as degranulation of mast cells.
- the allergic disease is food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, chronic idiopathic urticaria. (chronic idiopathic urticarial) and allergic contact dermatitis (allergic contact dermatitis) may be one selected from the group consisting of, but is not limited thereto.
- the allergic disease may be a disease mediated by IgE.
- the polypeptide dimer in the pharmaceutical composition, as long as the polypeptide dimer can exhibit anti-allergic activity, it may be included in an arbitrary amount (effective amount) depending on the use, formulation, purpose of combination, etc., and a typical effective amount is based on the total weight of the composition. It may be determined in the range of 0.001% to 20.0% by weight.
- the effective amount means an amount capable of inducing an anti-allergic effect. Such an effective amount can be determined by one of skill in the art.
- the pharmaceutical composition may additionally include a pharmaceutically acceptable carrier.
- the pharmaceutical composition may be prepared in an oral dosage form or a parenteral dosage form according to the route of administration by a conventional method known in the art, including a pharmaceutically acceptable carrier.
- suitable pharmaceutically acceptable carriers include sugars such as lactose, glucose, sucrose, dextrose, sorbitol, mannitol, and xylitol, corn starch, potato starch, wheat starch, and other starches, cellulose, methylcellulose, and ethylcellulose.
- Celluloses such as sodium carboxymethylcellulose, hydroxypropylmethylcellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate, mineral oil, malt, gelatin, talc, polyol, Vegetable oils and the like.
- it may include diluents and/or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
- the pharmaceutical composition When the pharmaceutical composition is prepared in a parenteral formulation, it may be formulated in the form of an injection, transdermal administration, topical administration, nasal inhalation and suppository according to a method known in the art together with a suitable carrier.
- a suitable carrier When formulated as an injection, sterile water, ethanol, polyols such as glycerol or propylene glycol, or mixtures thereof may be used as suitable carriers, preferably Ringer's solution, PBS (phosphate buffered saline) containing triethanol amine, or sterilization for injection Water, isotonic solutions such as 5% dextrose can be used.
- the formulation of the pharmaceutical composition is known in the art, and specifically, Remington's Pharmaceutical Sciences (19th ed., 1995) may be referred to.
- the preferred dosage of the pharmaceutical composition is in the range of 0.01 ⁇ g/kg to 10 g/kg per day, preferably 0.01 mg/kg to 1 g, depending on the patient's condition, weight, sex, age, patient severity, and route of administration. May be in the range of /kg.
- the pharmaceutical composition may be administered once a day or several times a day if the dosage is large.
- Subjects to which the pharmaceutical composition can be applied are mammals, for example, humans, dogs, and cats, particularly preferably humans, but are not limited thereto.
- the pharmaceutical composition may further include any known compounds or natural extracts, which have already been verified for safety and have anti-allergic activity, in order to increase or enhance anti-allergic activity.
- a polypeptide dimer having a high sialic acid content has better binding ability with IgE than a polypeptide dimer having a low sialic acid content (Table 3).
- a polypeptide dimer having a high sialic acid content is administered subcutaneously to an individual suffering from an allergic disease, it effectively reduces the concentration of IgE and MCPT-1 in the blood than a polypeptide dimer having a low sialic acid content, and a predetermined time has passed. It was confirmed that the effect persisted even after (FIGS. 13 and 14 ).
- another aspect of the present invention provides a transdermal patch comprising the pharmaceutical composition.
- another aspect of the present invention provides a topical patch comprising a pharmaceutical composition.
- Another aspect of the present invention provides a food composition for improving or alleviating allergic symptoms comprising a polypeptide dimer having a high sialic acid content.
- polypeptide dimer having a high sialic acid content is the same as described above.
- sialic acid-rich polypeptide dimer can be combined with an appropriate delivery means for efficient delivery into the intestine.
- the food composition may be prepared in any form, such as beverages such as tea, juice, carbonated beverages, ion beverages, processed oils such as milk, yogurt, tablets, capsules, pills, granules, liquids, powders, It can be prepared as a health functional food preparation such as flannel, paste, syrup, gel, jelly, bar, etc.
- the food composition may be classified as an arbitrary product as long as it conforms to the enforcement regulations at the time of manufacture and distribution in terms of legal and functional classification.
- it may be a health functional food according to the Health Functional Food Act, or confectionery, beans, tea, beverages, special purpose foods, etc., according to each food type according to the food code of the Food Sanitation Act (notified by the Ministry of Food and Drug Safety, food standards and standards).
- food code notified by the Ministry of Food and Drug Safety, food standards and standards.
- reference may be made to the food code or food additive code according to the Food Sanitation Act.
- Another aspect of the present invention provides a method for treating or preventing an allergic disease comprising administering to an individual a polypeptide dimer having a high sialic acid content.
- the polypeptide dimer having a high sialic acid content is the same as described above.
- the individual may be a mammal, preferably a human, a dog or a cat.
- administration may be administered orally or parenterally.
- parenteral administration may be performed by subcutaneous administration, intravenous administration, mucosal administration, and intramuscular administration.
- the allergic diseases include food allergy, atopic dermatitis, asthma, allergic rhinitis, allergic conjunctivitis, allergic dermatitis, and chronic idiopathic urticaria.
- allergic contact dermatitis may be one selected from the group consisting of.
- Another aspect of the present invention provides the use of the sialic acid-rich polypeptide dimer for preventing or treating allergic diseases.
- a polypeptide having a modified C-terminus of the extracellular domain of the alpha subunit of the IgE Fc receptor was prepared according to the method disclosed in US Pat. No. 7,867,491.
- the extracellular domain of the ⁇ chain of Fc ⁇ RI having the amino acid sequence of SEQ ID NO: 1 and the modified immunoglobulin Fc of SEQ ID NO: 2 are respectively linked by a linker of SEQ ID NO: 19 (Fc ⁇ RI ⁇ ECD-Fc1), a linker of SEQ ID NO: 3
- a cassette connecting the gene encoding each protein was cloned into the pAD15 vector (Genexine), and Fc ⁇ RI ⁇ ECD -Fc protein expression vector was constructed. Then, the expression vector was transfected into CHO DG44 (from Dr. Chasin, Columbia University, USA) cells, respectively.
- the expression vector in which the ⁇ -2,6-sialic acid transferase gene was cloned was simultaneously transfected into the pCI Hygro vector (Invitrogen) to express the sialic acid-added Fc ⁇ RI ⁇ ECD-Fc2ST and Fc ⁇ RI ⁇ ECD-Fc3ST proteins.
- a capable cell line was prepared separately.
- the Fc ⁇ RI ⁇ ECD-Fc3 cell line exhibited 16.9 ⁇ g/10 6 cell productivity after 2 ⁇ M methotrexat amplification.
- the Fc ⁇ RI ⁇ ECD-Fc3 cell line (Fc ⁇ RI ⁇ ECD-Fc3ST) co-transfected with 2,6-sialic acid transferase showed 10.2 ⁇ g/10 6 cells productivity after 1 ⁇ M methotrexat amplification.
- the Fc ⁇ RI ⁇ ECD-Fc2 cell line showed a productivity of 20.9 ⁇ g/10 6 cells under 0.5 ⁇ M methotrexat amplification conditions.
- the Fc ⁇ RI ⁇ ECD-Fc2 cell line (Fc ⁇ RI ⁇ ECD-Fc2ST) co-transfected with 2,6-sialic acid transferase showed a productivity of 25.1 ⁇ g/10 6 cells after 0.1 ⁇ M methotrexat amplification. That is, it was confirmed that the Fc ⁇ RI ⁇ ECD-Fc2ST cell line co-transfected with 2,6-sialic acid transferase selected under 0.1 ⁇ M methotrexat amplification conditions had the best productivity.
- the polypeptide produced from the Fc ⁇ RI ⁇ ECD-Fc2 cell line was named "Fc ⁇ RI ⁇ ECD-Fc2"
- the polypeptide produced from the Fc ⁇ RI ⁇ ECD-Fc2+a2,6-ST cell line was named "Fc ⁇ RI ⁇ ECD-Fc2ST”.
- the polypeptide produced from the Fc ⁇ RI ⁇ ECD-Fc3 cell line was named "Fc ⁇ RI ⁇ ECD-Fc3
- the polypeptide produced from the Fc ⁇ RI ⁇ ECD-Fc3+a2,6-ST cell line was named "Fc ⁇ RI ⁇ ECD-Fc3ST".
- the Fc ⁇ RI ⁇ ECD-Fc3 cell line i) the Fc ⁇ RI ⁇ ECD-Fc3+a2,6-ST cell line
- the Fc ⁇ RI ⁇ ECD-Fc2+a2,6-ST cell line was batch-cultured in a 60 ml medium volume (batch culture). After purifying Fc ⁇ RI ⁇ ECD-Fc using a Protein-A affinity column of the culture medium, the purified Fc ⁇ RI ⁇ ECD-Fc was subjected to size-exclusion high performance liquid chromatography (SE-HPLC) and SDS-PAGE to obtain the purity of the polypeptide. was confirmed.
- SE-HPLC size-exclusion high performance liquid chromatography
- SDS-PAGE was performed under non-reducing conditions.
- the non-reducing conditions are, after mixing each purified polypeptide with a non-reducing sample buffer, in Mini-Protean TGX TM gels (Bio-Rad) TGS (Tris Glycine SDS) buffer, under 200V conditions Electrophoresis was performed for 30 minutes. After electrophoresis, the protein was stained with Coomassie Brilliant Blue solution. The results are shown in Table 2 and FIG. 1.
- the Fc ⁇ RI ⁇ ECD-Fc3 cell line i) the Fc ⁇ RI ⁇ ECD-Fc3+a2,6-ST cell line, iii) the Fc ⁇ RI ⁇ ECD-Fc2+a2,6-ST cell line was batch-cultured in a 60 ml medium volume I did. Thereafter, the purified product obtained by purifying the polypeptide using the culture supernatant and the Protein-A affinity column was subjected to SE-HPLC and SDS-PAGE. At this time, the culture supernatant and the purified product were performed under non-reducing conditions and reducing conditions, respectively.
- each purified polypeptide was mixed with a reducing sample buffer containing 2-mercaptoethanol, and then denatured for 5 minutes at 100°C. . Thereafter, electrophoresis was performed on Mini-Protean TGX TM gels (Bio-Rad) for 30 minutes at 200V using a TGS buffer. After electrophoresis, the protein was stained with Coomassie Brilliant Blue solution.
- polypeptides of i) Fc ⁇ RI ⁇ ECD-Fc2, ii) Fc ⁇ RI ⁇ ECD-Fc2ST, iii) Fc ⁇ RI ⁇ ECD-Fc3 and iv) Fc ⁇ RI ⁇ ECD-Fc3ST produced in Example 1 were purified by the same method as in Example 2 and are commercially available. IgE binding strength was compared and measured with respect to the anti-IgE antibody, Omalizumab (trade name: Xolair).
- IgE binding ability is determined by coating IgE on the channel of the Protein GLC sensor chip (Bio-Rad, Cat #. 176-5011), and omalizumab or each FceR1 ⁇ ECD-Fc protein at various concentrations at a rate of 30 ⁇ l/min. I spilled it. At this time, after confirming the zero-base using a sodium hydroxide solution having a concentration of 25 mM as a regeneration buffer, the above steps were repeated to measure. Thereafter, a binding curve was confirmed using a protein binding analyzer (Proteon XPR36, BIO-RAD, USA), and the results are shown in Table 3.
- the association rate (ka) value of the polypeptide dimer and IgE according to an embodiment of the present invention was measured to be 1.5 to 2.0 times smaller than that of omalizumab. That is, it was found that the binding force with substances other than IgE was 1.5 to 2.0 times lower than that of omalizumab.
- the dissociation rate (kd) value of the polypeptide dimer according to an embodiment of the present invention was measured to be 40 to 106 times greater than that of omalizumab.
- the value of the equilibrium dissociation constant (KD ⁇ kd/ka>) of the polypeptide dimer according to an embodiment of the present invention is 22 to 69 times higher than that of omalizumab.
- the polypeptide dimer according to an embodiment of the present invention has a remarkably increased binding capacity to IgE compared to omalizumab.
- the polypeptide dimer to which sialic acid was added had the best IgE binding ability, 69 times as compared to omalizumab.
- omalizumab is degraded after a certain time after binding to IgE, whereas the polypeptide dimer (Fc ⁇ RI ⁇ ECD-Fc2ST, IgE TRAP ) according to an embodiment of the present invention is once IgE After combining with, it was confirmed that it did not separate from IgE. That is, it was confirmed that the polypeptide dimer according to an embodiment of the present invention was not easily separated from IgE, and the ability to remain in a bound state was superior to omalizumab.
- the ability of the polypeptide dimer (Fc ⁇ RI ⁇ ECD-Fc2ST, IgE TRAP ) or omalizumab (Xolair) to bind to the Fc gamma receptor of the polypeptide according to an embodiment of the present invention was measured using the Octet RED384 system (Pall ForteBio, CA, USA) And confirmed.
- Fc gamma receptors Fc ⁇ RI, Fc ⁇ RIIA, Fc ⁇ RIIB, Fc ⁇ RIIIA or Fc ⁇ RIIIB recombinant protein were immobilized in 300 mM acetate buffer (pH 5) on the activated AR2G biosensor.
- PBS containing 0.1% Tween-20 and 1% bovine serum (BS) was used as a running buffer. All measurements were performed at a temperature of 30° C. at a speed of 1,000 rpm on a sample plate shaker. The measurement results are shown in FIGS. 5A to 5E, and the binding ability of omalizumab and the polypeptide dimer to the IgG Fc gamma receptor is quantified and shown in FIG. 6.
- omalizumab showed a high binding ability with the Fc gamma receptor of IgG, while the polypeptide dimer had a remarkably low binding ability with the Fc gamma receptor of IgG.
- the polypeptide dimer did not bind to the Fc gamma receptor of IgG.
- beta-hexosaminidase analysis was performed.
- a polypeptide dimer (Fc ⁇ RI ⁇ ECD-Fc2) was mixed with IgE (1 ⁇ g/ml) by concentration, and incubated at a temperature of 20° C. for 30 minutes to prepare a sample.
- the cultured mouse bone marrow-derived mast cells for mast cell activation were washed with HBSS (Hank's balanced salt solution) buffer to remove the medium. After measuring the number of cells, 5x10 5 cells were removed in 40 ⁇ l Resuspended in HBSS buffer.
- Each of the polypeptide dimers and Xolere were prepared by concentration, mixed with human IgE (1 ⁇ g/ml), and incubated at room temperature for 30 minutes to prepare a sample.
- human IgE 1 ⁇ g/ml
- mast cells derived and differentiated from the bone marrow of a mouse into which the human Fc ⁇ RI gene was introduced and the mouse Fc ⁇ RI gene was removed were prepared. After the prepared mast cells were washed with HBSS buffer, 5 ⁇ 10 5 cells were resuspended in 60 ⁇ l of HBSS buffer.
- the IC 50 of the polypeptide dimer was measured to be approximately 11.16 ng/ml, and the IC 50 of Xolair was measured to be approximately 649.8 ng/ml. Therefore, it was confirmed that the polypeptide dimer has a mast cell activity inhibitory ability that is 58 times higher than that of Xolair.
- mice After oral administration of the OVA twice, the mice were classified into three groups of 7 mice each on the 31st day.
- the first group the group administered with a high concentration (200 ⁇ g) of the polypeptide dimer (Fc ⁇ RI ⁇ ECD-Fc2ST), the second group, the group administered with a low concentration (20 ⁇ g), and the third group, the group not administered were classified.
- mice were sacrificed on day 37 to analyze the number of mast cells in the small intestine, the concentration of IgE in the blood, and the concentration of degranulation enzymes (MCPT-1, Mast cell protease-1) of the mast cells in the blood for mice belonging to each group.
- MCPT-1 degranulation enzymes
- mice of the third group As a result, as shown in FIG. 9, diarrhea occurred in the mice of the third group after oral administration of the second OVA.
- the mice of the first and second groups developed diarrhea after oral administration of the third OVA.
- the mice of the first group had a lower incidence of diarrhea than the mice of the second group, and through this, it was confirmed that the food allergic effect increased in proportion to the concentration of the polypeptide dimer.
- Example 1 The production rate of the polypeptide produced from the Fc ⁇ RI ⁇ ECD-Fc2+a2,6-ST cell line is the highest, and in Experimental Examples 4 to 6, the anti-allergic effect of the polypeptide dimer (Fc ⁇ RI ⁇ ECD-Fc2ST) is excellent.
- the sialic acid content of the polypeptide dimer (Fc ⁇ RI ⁇ ECD-Fc2ST) was analyzed to determine the anti-allergic efficacy of the polypeptide dimer.
- Example 1 prepared in Example 1 In order to measure the sialic acid content contained in the glycan structure of the polypeptide dimer (Fc ⁇ RI ⁇ ECD-Fc2ST) produced from the Fc ⁇ RI ⁇ ECD-Fc2+a2,6-ST cell line, first, sialidase, a sialic acid-degrading enzyme. ) To separate sialic acid. Then, the separated sialic acid was separated, detected, and quantified using HPLC (waters, alliance e2659).
- HPLC waters, alliance e2659
- the polypeptide dimer was separated and purified by dividing into three samples according to the pH gradient. Three samples were placed in an AmiconUltra 10K (Millipore, UFC501096) filter, centrifuged for 10 minutes under conditions of 13,000 rpm and 4°C, and repeated 5 times to exchange the concentrate with deionized water and concentrated. The concentration of the sample was 10 mg/ml or more when measured at a wavelength of 280 nm.
- the sample was reacted in an incubator at 37° C. for 18 hours, then placed in an AmiconUltra 10K filter, centrifuged at 13,000 rpm and 4° C. for 15 minutes, and the filtrate exiting the filter was used for analysis.
- HPLC analysis conditions are shown in Table 4 below.
- the standard material for calculating the sialic acid content is a mixture of N-acetylneuraminic acid (N-acetylneuraminic acid, hereinafter referred to as NANA) and N-glycolylneuraminic acid (N-glycolylneuraminic acid, hereinafter referred to as NGNA).
- NANA N-acetylneuraminic acid
- NGNA N-glycolylneuraminic acid
- the NANA sialic acid content of the sample was calculated using the NANA content.
- the sialic acid content of the sample was expressed as a sialic acid/sample mole ratio (mol/mol).
- Sialic acid content of the sample (NANA molar concentration of the sample)/(Molar concentration of the sample)
- the NGNA content of the sample was calculated using the NGNA content.
- the content of NGNA in the sample was expressed as the NGNA/analytical sample molar ratio (mol/mol).
- the sialic acid content of the samples separated and purified by dividing into three samples according to the pH gradient was measured differently.
- SA low In order to compare the anti-allergic efficacy according to the sialic acid content, it was named "SA low ", “SA medi” and "SA high " in the order of sialic acid content.
- sensitization was induced by intraperitoneal administration of 50 ⁇ g of OVA and 1 mg of Alum to Balb/c mice (Orientbio) at 14 days intervals. Thereafter, on days 28, 30, 32, 34, 36, 38, and 40, OVA 50 mg was orally administered over a total of 7 times to induce food allergy. At this time, oral administration of OVA was performed after fasting for 4 hours.
- mice After oral administration of the OVA twice, the mice were classified into 3 groups of 7 mice each on the 40th day.
- the first group a group in which a polypeptide dimer having a high sialic acid content (SA high ) is administered subcutaneously at a high concentration (200 ⁇ g)
- a second group a polypeptide dimer having a low sialic acid content (SA low )
- SA high a polypeptide dimer having a high sialic acid content
- SA low a polypeptide dimer having a low sialic acid content
- mice of the third group had diarrhea after oral administration of the fourth OVA.
- the second group of mice developed diarrhea after oral administration of the fifth OVA.
- the incidence of diarrhea rapidly increased in mice in the second group after oral administration of the 6th OVA.
- diarrhea occurred after oral administration of the 6th OVA, but the incidence of diarrhea did not increase even after oral administration of the 7th OVA (FIG. 12 ).
- SA high polypeptide dimer having a high sialic acid content
- SA low a polypeptide dimer having a low sialic acid content
- a 96-well plate was coated with a polypeptide dimer diluted in PBS (SA low and SA high ), and reacted at 4°C overnight. The next day, after washing with PBS containing 0.05% tween 20 (hereinafter, washing buffer), a blocking buffer (assay diluent) was added and reacted for 1 hour. Thereafter, after washing with a washing buffer, mouse IgE to be used as a standard solution and a serum sample of a mouse were diluted in 1X assay diluent, placed in a plate, and reacted for 2 hours.
- washing buffer PBS containing 0.05% tween 20
- assay diluent assay diluent
- the blood IgE concentration was calculated to be about 8,000 ng/ml.
- the concentration of IgE in the blood was calculated to be about 7,000 ng/ml.
- SA high polypeptide dimer having a high sialic acid content
- a 96-well-immune plate was coated with a mouse anti-MCPT-1 antibody and reacted at 4°C overnight.
- the next day after washing with PBS containing 0.05% tween 20 (hereinafter, washing buffer), PBS containing 1% BSA (Bovine serum albumin) (hereinafter referred to as blocking buffer, assay diluent) was added and reacted for 1 hour.
- PBS containing 1% BSA Bovine serum albumin
- blocking buffer assay diluent
- the concentration of MCPT-1 in the blood was calculated to be about 4,000 ng/ml.
- the concentration of MCPT-1 in blood was calculated to be about 4,200 ng/ml.
- SA high polypeptide dimer having a high sialic acid content
- Example 3 Preparation of a polypeptide dimer containing a high content of sialic acid through purification
- polypeptide dimer containing various ranges of sialic acid was obtained. Specifically, the polypeptide dimer obtained from the Fc ⁇ RI ⁇ ECD-Fc2+a2,6-ST cell line was purified using affinity chromatography and anion exchange chromatography.
- the cell culture solution was subjected to affinity chromatography to remove primary impurities from the culture solution.
- Affinity chromatography is Amshpere TM A3 resin is packed (packing) the Amsphere TM A3 pre-packed column (Amsphere TM A3 pre-packed column ; bed height (bed hight) 5 cm, bulk (volume) 5 ml) and liquid chromatography It was carried out using the AKTA Avant 25 equipment, which is a graphic system. At this time, the elution buffer was performed using 100 mM Glycine, pH 3.3.
- the sialic acid content of 7.0 mol/mol, 10.3 mol/mol, 12.9 mol/mol, 14.9 mol/mol and 21.4 mol/ prepared in Example 3 Moles of the polypeptide dimers were injected subcutaneously into mice at a concentration of 10 mg/kg each.
- blood was collected at 0 hours, 3 hours, 10 hours, 24 hours, 72 hours, 168 hours, and 240 hours after administration of the substance and analyzed by the following method.
- Anti-Fc ⁇ RI antibody (Invitrogen) was diluted in 1X PBS (Welgene) to a concentration of 0.5 ⁇ g/ml, added to an immunoplate (Thermo), and reacted overnight at 4°C. The immunoplate after the reaction was washed with 1X PBST, and I-Block solution (invitrogen), a blocking solution, was added per well and reacted at room temperature for 1 hour. During blocking, a standard and a sample for analysis were prepared.
- the polypeptide dimer was diluted in 1% BSA/PBS containing mouse blank serum at a concentration of 0.19 ng/ml to 200 ng/ml and prepared as a standard material, and the sample for analysis was also 1% BSA/PBS containing blank serum. It was prepared by diluting it to 1/20-1/300 using.
- the plate after blocking was washed with 1X PBST, and the prepared standard and sample for analysis were added per well, and then reacted at room temperature for 1 hour.
- anti-human IgG4-HRP Southern biotech
- TMB solution TMB solution
- the plate on which the reaction was terminated was measured for absorbance and numerical analysis at 450 nm wavelength within 5 minutes.
- the resulting pharmacokinetic graph and pharmacokinetic parameter results of the polypeptide dimer according to the resulting sialic acid content are shown in FIGS. 15 and 7.
- Transponder-inserted Balb/c mice measured body temperature and administered intraperitoneally with 20 ⁇ g of anti-DNP IgE (Sigma) containing 0.9% NaCl, and polypeptides with different sialic acid contents 10 mg/kg of the dimer was injected subcutaneously. After 24 hours, the mouse body temperature was measured before administration of DNP-HAS (Sigma) containing 0.9% NaCl of foreign antigen. Thereafter, 1 mg of antigen was administered intravenously. After administration, the mouse body temperature was measured for 1 hour at 10-minute intervals using a remote thermometer (Bio medic data systems). The experimental results are shown in FIG. 16.
- the mouse body temperature decreased in the group administered with the vehicle and the sialic acid content of 10.3 mol/mol polypeptide dimer, but the mouse body temperature did not decrease in the group having a sialic acid content of 14.9 mol/mol or more.
- the polypeptide dimer having a high sialic acid content is superior to the dimer having a low sialic acid content in reducing the induction of passive systemic anaphylaxis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Version | Media | MTX conc. | Productivity | ||
3-day culture | Batch culture(㎎/㎖) | ||||
㎍/㎖ | ㎍/106 cells | ||||
FcεRIαECD-Fc2 | Ex-cellDHFR | 500nM | 37.23 | 20.9 | 225 |
FcεRIαECD-Fc2+a2,6-ST | 100nM | 45.4 | 25.1 | 338.2 | |
FcεRIαECD-Fc3 | 2uM | 27.0 | 16.9 | 180.4 | |
FcεRIαECD-Fc3+a2,6-ST | 1uM | 17.5 | 10.2 | 101.7 |
Lane # | Sample | Purification | Purity(SE-HPLC) | Sample condition | |
M | Protein standard | One-step(Protein-A affinity column)Purification | - | - | - |
1 | FcεRIαECD-Fc3 | 94.5% | - | Non-reducing | |
2 | FcεRIαECD-Fc3ST | 93.7% | |||
3 | FcεRIαECD-Fc2ST | 93.2% | |||
4 | FcεRIαECD-Fc3 | 94.5% | Freezing/Thawingtest | ||
5 | FcεRIαECD-Fc3ST | 93.7% | |||
6 | FcεRIαECD-Fc2ST | 93.2% |
SamplesItems | FcεRIa ECD-Fc | 오말리주맙 | 비고 | ||
Drug type | Fc 융합 단백질 | Anti-IgE Ab | |||
Bindingaffinity | ka (Association rate) | Fc2 | 2.14 x 105 | 4.05 x 105 | 오말리주맙 대비 1.9배 약함 |
Fc2ST | 2.64 x 105 | 오말리주맙 대비 1.5배 약함 | |||
Fc3 | 1.98 x 105 | 오말리주맙 대비 2.0배 약함 | |||
Fc3ST | 2.40 x 105 | 오말리주맙 대비 1.7배 약함 | |||
kd (Dissociation rate) | Fc2 | 8.29 x 10-5 | 6.02 x 10-3 | 오말리주맙 대비 73배 좋음 | |
Fc2ST | 5.69 x 10-5 | 오말리주맙 대비 106배 좋음 | |||
Fc3 | 1.33 x 10-4 | 오말리주맙 대비 45배 좋음 | |||
Fc3ST | 1.49 x 10-4 | 오말리주맙 대비 40배 좋음 | |||
KD (kd/ka) | Fc2 | 3.88 x 10-10 | 1.49 x 10-8 | 오말리주맙 대비 38배 좋음 | |
Fc2ST | 2.16 x 10-10 | 오말리주맙 대비 69배 좋음 | |||
Fc3 | 6.72 x 10-10 | 오말리주맙 대비 22배 좋음 | |||
Fc3ST | 6.21 x 10-10 | 오말리주맙 대비 24배 좋음 |
분석컬럼 | RHM-monosaccharide H+ (8%) 300 Х 7.8 mm (Rezex); 분석칼럼RHM-monosaccharide H+ (8%) 50 Х 7.8 mm (Rezex); 가드칼럼 |
표준물질 | NGNA: 2 ~ 40 μMNANA: 100 ~ 2000 μM |
유량 | 0.55 ㎖/min |
컬럼 온도 | 50℃ |
검출(Detection) | 206 nm |
주입량 | 5 ㎕ |
이동상 | 5 mN sulfuric acid in water |
그래디언트/시간(Gradient / time) | 등용매용리 / 45 분 |
혼합물 | 1 | 2 | 3 | 4 | 5 |
NANA (μM) | 2,000 | 1,000 | 500 | 300 | 200 |
NGNA (μM) | 40 | 20 | 10 | 6 | 4 |
시료 | NGNA/Protein(mol/mol) | NANA/Protein(mol/mol) | |
FcεRIαECD-Fc2ST | 시료 1 (SAlow) | 0.13 | 7.7 |
시료 2 (SAmedi) | 0.17 | 12.0 | |
시료 3 (SAhigh) | 0.27 | 19.1 |
시알산 함량 (mol/mol) | T1/2 (hr) | Tmax (hr) | Cmax (㎍/㎖) | AUClast (hr*㎍/㎖) |
7.0 | 51.3 ± 5.9 | 5.3 ± 3.3 | 1.3 ± 0.5 | 47.8 ± 3.2 |
10.3 | 44.5 ± 6.7 | 5.3 ± 3.3 | 1.6 ± 0.6 | 57.1 ± 9.6 |
12.9 | 40.0 ± 9.5 | 17 ± 9.9 | 2.0 ± 0.4 | 119.7 ± 5.2 |
14.9 | 35.4 ± 3.5 | 7.7 ± 3.3 | 2.6 ± 0.3 | 182.7 ± 7.0 |
21.4 | 38.5 ± 5.0 | 10.0 ± 0.0 | 12.1 ± 0.9 | 890.0 ± 64.4 |
Claims (17)
- IgE Fc 수용체의 알파 서브유닛의 세포외 도메인(FcεRIa-ECD)을 포함하는 단량체 두 개를 포함하는 폴리펩티드 이량체로서,상기 단량체는 Fc 영역을 포함하며,상기 Fc 영역과 FcεRIa-ECD는 힌지를 통해 결합되고,상기 폴리펩티드 이량체는 시알산/폴리펩티드 이량체의 몰 비율이 적어도 8인 것인, 시알산 함량이 높은 폴리펩티드 이량체.
- 제1항에 있어서,상기 IgE Fc 수용체의 알파 서브유닛의 세포외 도메인은 서열번호 1의 아미노산 서열로 이루어진 것인, 시알산 함량이 높은 폴리펩티드 이량체.
- 제1항에 있어서,상기 Fc 영역은 서열번호 2로 표시되는 아미노산 서열로 이루어진 것인, 시알산 함량이 높은 폴리펩티드 이량체.
- 제1항에 있어서,상기 힌지는 면역글로불린 IgD에서 유래한 힌지 영역 또는 이의 변이체인 것인, 시알산 함량이 높은 폴리펩티드 이량체.
- 제1항에 있어서,상기 시알산은 N-아세틸뉴라민산인 것인, 시알산 함량이 높은 폴리펩티드 이량체.
- 제1항에 있어서,상기 폴리펩티드 이량체는 시알산/폴리펩티드 이량체의 몰 비율이 적어도 10인 것인, 시알산 함량이 높은 폴리펩티드 이량체.
- 제6항에 있어서,상기 폴리펩티드 이량체는 시알산/폴리펩티드 이량체의 몰 비율이 12 내지 25인 것인, 시알산 함량이 높은 폴리펩티드 이량체.
- 제4항에 있어서,상기 면역글로불린 IgD에서 유래한 힌지 영역 또는 이의 변이체는 적어도 하나의 시스테인을 포함하는 것인, 시알산 함량이 높은 폴리펩티드 이량체.
- 제4항에 있어서,상기 면역글로불린 IgD에서 유래한 힌지 영역 또는 이의 변이체는Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa1 Xaa2 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro(서열번호 17),이때, Xaa1은 Lys 또는 Gly이며, Xaa2는 Glu, Gly 또는 Ser인; 또는Ala Gln Pro Gln Ala Glu Gly Ser Leu Ala Lys Ala Thr Thr Ala Pro Ala Thr Thr Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Xaa3 Xaa4 Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro (서열번호 18),이때, Xaa3은 Lys 또는 Gly이며, Xaa4는 Glu, Gly 또는 Ser인,시알산 함량이 높은 폴리펩티드 이량체.
- 제4항에 있어서,상기 면역글로불린 IgD에서 유래한 힌지 영역 또는 이의 변이체가 서열번호 3, 서열번호 4 및 서열번호 19로 이루어진 군에서 선택되는 어느 하나의 아미노산 서열로 이루어진 것인, 시알산 함량이 높은 폴리펩티드 이량체.
- 제1항 내지 제10항 중 어느 한 항에 따른 시알산 함량이 높은 폴리펩티드 이량체를 포함하는 알러지 질환 예방 또는 치료용 약학적 조성물.
- 제11항에 있어서, 상기 약학적 조성물은 피하 주사제용인 것인, 알러지 질환 예방 또는 치료용 약학적 조성물.
- 제11항에 있어서,상기 알러지 질환은 식품 알러지, 아토피 피부염(atopic dermatitis), 천식(asthma), 알러지성 비염(allergic rhinitis), 알러지성 결막염(allergic conjunctivitis), 알러지성 피부염(allergic dermatitis), 만성 특발성 두드러기(Chronic idiopathic urticarial) 및 알러지성 접촉성 피부염(allergic contact dermatitis)으로 구성된 군에서 선택된 하나인 것인, 알러지 질환 예방 또는 치료용 약학적 조성물.
- 제11항의 약학적 조성물을 포함하는 경피 패치(transdermal patch).
- 제11항의 약학적 조성물을 포함하는 국소 패치(topical patch).
- 제1항 내지 제10항 중 어느 한 항에 따른 시알산 함량이 높은 폴리펩티드 이량체를 포함하는 알러지 증상 개선 또는 완화용 식품 조성물.
- 알러지 질환 예방 또는 치료를 위한 제1항 내지 제10항 중 어느 한 항에 따른 시알산 함량이 높은 폴리펩티드 이량체의 용도.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020310003A AU2020310003A1 (en) | 2019-07-08 | 2020-07-07 | Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IgE Fc receptor, and pharmaceutical composition comprising same |
MX2022000285A MX2022000285A (es) | 2019-07-08 | 2020-07-07 | Dimero de polipeptido con alto contenido de acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige y composicion farmaceutica que comprende el mismo. |
CN202080049890.9A CN114080398B (zh) | 2019-07-08 | 2020-07-07 | 包含IgE Fc受体的α亚基的胞外结构域且具有高唾液酸含量的多肽二聚体及包含其的药物组合物 |
CA3145382A CA3145382A1 (en) | 2019-07-08 | 2020-07-07 | Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising same |
BR112022000246A BR112022000246A2 (pt) | 2019-07-08 | 2020-07-07 | Dímero polipeptídico com elevado teor de ácido siálico, compreendendo o domínio extracelular da subunidade alfa do receptor fc de ige e composição farmacêutica compreendendo o mesmo |
JP2021575270A JP2022539684A (ja) | 2019-07-08 | 2020-07-07 | 高シアル酸含量を有し、IgE Fc受容体のアルファサブユニットの細胞外ドメインを含むポリペプチド二量体及び同ポリペプチド二量体を含む医薬組成物 |
EP20837726.7A EP3998279A4 (en) | 2019-07-08 | 2020-07-07 | HIGH SIALIC ACID POLYPEPTIDE DIMERS COMPRISING EXTRACELLULAR IGE FC RECEPTOR ALPHA SUBUNIT DOMAIN AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
PE2022000024A PE20220098A1 (es) | 2019-07-08 | 2020-07-07 | Dimero polipeptido con alto contenido en acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige, y composicion farmaceutica que comprende el mismo |
US17/625,668 US20220257693A1 (en) | 2019-07-08 | 2020-07-07 | Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising same |
IL289679A IL289679A (en) | 2019-07-08 | 2022-01-06 | A dimer polypeptide with a high sialic acid content, containing an extracellular domain of the alpha subunit of the ige fc receptor and a pharmaceutical preparation containing it |
ZA2022/00738A ZA202200738B (en) | 2019-07-08 | 2022-01-14 | Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190082217 | 2019-07-08 | ||
KR10-2019-0082217 | 2019-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021006599A1 true WO2021006599A1 (ko) | 2021-01-14 |
Family
ID=74115108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/008855 WO2021006599A1 (ko) | 2019-07-08 | 2020-07-07 | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220257693A1 (ko) |
EP (1) | EP3998279A4 (ko) |
JP (1) | JP2022539684A (ko) |
KR (2) | KR102561135B1 (ko) |
CN (1) | CN114080398B (ko) |
AU (1) | AU2020310003A1 (ko) |
BR (1) | BR112022000246A2 (ko) |
CA (1) | CA3145382A1 (ko) |
CL (1) | CL2021003401A1 (ko) |
IL (1) | IL289679A (ko) |
MX (1) | MX2022000285A (ko) |
PE (1) | PE20220098A1 (ko) |
TW (1) | TWI764191B (ko) |
WO (1) | WO2021006599A1 (ko) |
ZA (1) | ZA202200738B (ko) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3067334A (en) | 1959-03-13 | 1962-12-04 | Garrett Corp | Driving and control means for a plurality of alternators |
WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
US20080300188A1 (en) * | 2007-05-30 | 2008-12-04 | Genexine Co., Ltd | Immunoglobulin Fusion Proteins |
KR20170041384A (ko) * | 2015-10-07 | 2017-04-17 | 주식회사 녹십자 | 지속형 에리트로포이에틴 함유 조성물 |
KR101783272B1 (ko) | 2008-09-17 | 2017-09-29 | 젠코어 인코포레이티드 | IgE-매개된 장애를 치료하기 위한 신규 조성물 및 방법 |
KR20170120579A (ko) * | 2015-02-20 | 2017-10-31 | 키세이 야쿠힌 고교 가부시키가이샤 | Fc-융합 고친화성 IgE 수용체 알파 사슬 |
KR20190084886A (ko) * | 2018-01-08 | 2019-07-17 | 주식회사 프로젠 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 |
KR20190084885A (ko) * | 2018-01-08 | 2019-07-17 | 주식회사 프로젠 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100475417B1 (ko) * | 1998-12-30 | 2005-07-18 | 씨제이 주식회사 | 시알산 함량이 높은 재조합 당단백질의 제조방법 |
CN105175553B (zh) * | 2007-05-30 | 2019-11-22 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
AU2010315470B2 (en) * | 2009-10-26 | 2016-05-05 | Genentech, Inc. | Assays for detecting antibodies specific to therapeutic anti-IgE antibodies and their use in anaphylaxis |
WO2012053828A2 (ko) * | 2010-10-20 | 2012-04-26 | 주식회사 한독약품 | 인간 인터루킨-1 수용체 길항제-하이브리드 Fc 융합단백질 |
WO2014144621A2 (en) * | 2013-03-15 | 2014-09-18 | Pyranose Biotherapeutics, Inc. | Modified fc fusion proteins |
KR20150135148A (ko) * | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
RU2708160C2 (ru) * | 2015-06-11 | 2019-12-04 | Дженексин, Инк. | Модифицированный белок интерлейкина-7 и способы его применения |
PE20210108A1 (es) * | 2018-01-12 | 2021-01-19 | Gi Innovation Inc | Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma |
-
2020
- 2020-07-07 WO PCT/KR2020/008855 patent/WO2021006599A1/ko unknown
- 2020-07-07 MX MX2022000285A patent/MX2022000285A/es unknown
- 2020-07-07 KR KR1020200083486A patent/KR102561135B1/ko active IP Right Grant
- 2020-07-07 AU AU2020310003A patent/AU2020310003A1/en active Pending
- 2020-07-07 JP JP2021575270A patent/JP2022539684A/ja active Pending
- 2020-07-07 EP EP20837726.7A patent/EP3998279A4/en active Pending
- 2020-07-07 US US17/625,668 patent/US20220257693A1/en active Pending
- 2020-07-07 PE PE2022000024A patent/PE20220098A1/es unknown
- 2020-07-07 BR BR112022000246A patent/BR112022000246A2/pt unknown
- 2020-07-07 CA CA3145382A patent/CA3145382A1/en active Pending
- 2020-07-07 CN CN202080049890.9A patent/CN114080398B/zh active Active
- 2020-07-08 TW TW109123074A patent/TWI764191B/zh active
-
2021
- 2021-12-17 CL CL2021003401A patent/CL2021003401A1/es unknown
-
2022
- 2022-01-06 IL IL289679A patent/IL289679A/en unknown
- 2022-01-14 ZA ZA2022/00738A patent/ZA202200738B/en unknown
-
2023
- 2023-07-24 KR KR1020230096002A patent/KR20230115283A/ko not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3067334A (en) | 1959-03-13 | 1962-12-04 | Garrett Corp | Driving and control means for a plurality of alternators |
WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
US20080300188A1 (en) * | 2007-05-30 | 2008-12-04 | Genexine Co., Ltd | Immunoglobulin Fusion Proteins |
US7867491B2 (en) | 2007-05-30 | 2011-01-11 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
KR101783272B1 (ko) | 2008-09-17 | 2017-09-29 | 젠코어 인코포레이티드 | IgE-매개된 장애를 치료하기 위한 신규 조성물 및 방법 |
KR20170120579A (ko) * | 2015-02-20 | 2017-10-31 | 키세이 야쿠힌 고교 가부시키가이샤 | Fc-융합 고친화성 IgE 수용체 알파 사슬 |
KR20170041384A (ko) * | 2015-10-07 | 2017-04-17 | 주식회사 녹십자 | 지속형 에리트로포이에틴 함유 조성물 |
KR20190084886A (ko) * | 2018-01-08 | 2019-07-17 | 주식회사 프로젠 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 |
KR20190084885A (ko) * | 2018-01-08 | 2019-07-17 | 주식회사 프로젠 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
Non-Patent Citations (4)
Title |
---|
"Methods and Protocols, Methods in Molecular Biology", vol. 1032 |
"Remington's Pharmaceutical Sciences", 1995 |
TAKAHASHI K; RA C: "The high affinity IgE receptor (Fc[epsilon]RI) as a target for anti-allergic agents", ALLERGOLOGY INTERNATIONAL, JAPANESE SOCIETY OF ALLERGOLOGY, JP, vol. 54, no. 1, 1 January 2005 (2005-01-01), JP, pages 1 - 5, XP009102529, ISSN: 1323-8930, DOI: 10.2332/allergolint.54.1 * |
THE JOURNAL OF CLINICAL INVESTIGATION, vol. 99, no. 5, March 1997 (1997-03-01), pages 915 - 925 |
Also Published As
Publication number | Publication date |
---|---|
BR112022000246A2 (pt) | 2022-02-22 |
EP3998279A1 (en) | 2022-05-18 |
KR20230115283A (ko) | 2023-08-02 |
CA3145382A1 (en) | 2021-01-14 |
ZA202200738B (en) | 2023-11-29 |
JP2022539684A (ja) | 2022-09-13 |
PE20220098A1 (es) | 2022-01-24 |
IL289679A (en) | 2022-03-01 |
KR102561135B1 (ko) | 2023-07-31 |
TW202116799A (zh) | 2021-05-01 |
AU2020310003A1 (en) | 2022-01-06 |
EP3998279A4 (en) | 2023-01-18 |
CL2021003401A1 (es) | 2022-10-14 |
KR20210006293A (ko) | 2021-01-18 |
CN114080398B (zh) | 2024-05-31 |
MX2022000285A (es) | 2022-02-03 |
TWI764191B (zh) | 2022-05-11 |
CN114080398A (zh) | 2022-02-22 |
US20220257693A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7488303B2 (ja) | IgE Fc受容体のアルファサブユニットの細胞外ドメイン、その物を含む医薬組成物、およびその物を製造する方法 | |
WO2013051900A2 (en) | Blood coagulation factor ⅶ and ⅶa derivatives, conjugates and complexes comprising the same, and use thereof | |
WO2015005747A1 (ko) | FcRn 결합력이 유지되는 면역글로불린 Fc 결합체 | |
WO2021071319A1 (ko) | 다중 특이적 융합 단백질 및 이의 용도 | |
Ling et al. | Human type I interferon receptor, IFNAR, is a heavily glycosylated 120-130 kD membrane protein | |
WO2021154046A1 (ko) | pH-감응성 FC 변이체 | |
WO2019135666A1 (ko) | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 | |
WO2019139434A1 (ko) | 프로바이오틱스 및 ige에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도 | |
WO2021006599A1 (ko) | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물 | |
WO2021107603A2 (en) | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same | |
EP2588142A2 (en) | Factor viia complex using an immunoglobulin fragment | |
WO2021006375A1 (ko) | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물 | |
WO2023214833A1 (ko) | Glp-1, 면역글로불린 fc, 및 igf-1을 포함하는 융합단백질 및 이의 용도 | |
WO2022010273A1 (ko) | 보체 경로 억제제를 포함하는 융합단백질 및 이의 용도 | |
WO2022019652A1 (ko) | IgE Fc 수용체를 포함하는 융합단백질 및 이를 포함하는 개 알레르기성 질환 치료 용도 | |
WO2020138868A1 (ko) | 타입 1 인터페론 중화 fc-융합 단백질 및 이의 용도 | |
WO2022015049A1 (ko) | IgE Fc 수용체 알파서브유닛의 세포외 도메인 및 항-IL-4R 항체를 포함하는 융합단백질 및 이의 용도 | |
WO2021034098A1 (ko) | 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 또는 이의 변이체를 포함하는 면역사이토카인의 용도 | |
WO2022265331A1 (ko) | 제어된 면역 작용 기작과 증가된 혈중 반감기를 갖는 fc변이체들 | |
WO2024005424A1 (ko) | FCγRIIA 결합 선택성이 향상된 인간 FC 변이체 | |
WO2024043643A1 (ko) | Il2 변이체 및 이를 포함하는 단백질 복합체 | |
WO2024005423A1 (ko) | 인간 FCγRS 결합력이 제거된 당화 FC 변이체들 | |
WO2021230705A1 (ko) | 신규 재조합 융합단백질 및 그의 용도 | |
WO2022092644A1 (ko) | Wars 중화항체 및 이의 용도 | |
WO2023287238A1 (ko) | 뇌혈관장벽 통과 효율이 향상된 항 인간 트랜스페린 수용체 항체, 및 이를 이용한 다중특이적 항체 및 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20837726 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021575270 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3145382 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020310003 Country of ref document: AU Date of ref document: 20200707 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022000246 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020837726 Country of ref document: EP Effective date: 20220208 |
|
ENP | Entry into the national phase |
Ref document number: 112022000246 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220106 |